Please use this identifier to cite or link to this item: https://doi.org/10.1016/j.leukres.2013.06.008
Title: The impact of upfront versus sequential use of bortezomib among patients with newly diagnosed multiple myeloma (MM): A joint analysis of the Singapore MM Study Group and the Korean MM Working Party for the Asian myeloma network
Authors: Tan, D.
Kim, K.
Kim, J.S.
Eom, H.-S.
Teoh, G.
Ong, K.H.
Goh, Y.T.
Durie, B.G.M.
Chng, W.J. 
Lee, J.H.
Keywords: Bortezomib
ISS
Myeloma
Issue Date: Sep-2013
Citation: Tan, D., Kim, K., Kim, J.S., Eom, H.-S., Teoh, G., Ong, K.H., Goh, Y.T., Durie, B.G.M., Chng, W.J., Lee, J.H. (2013-09). The impact of upfront versus sequential use of bortezomib among patients with newly diagnosed multiple myeloma (MM): A joint analysis of the Singapore MM Study Group and the Korean MM Working Party for the Asian myeloma network. Leukemia Research 37 (9) : 1070-1076. ScholarBank@NUS Repository. https://doi.org/10.1016/j.leukres.2013.06.008
Abstract: From the comprehensive MM registries of the Singapore (SG) and South Korea (SK) MM study groups, we study the survival data of 432 unselected and previously untreated MM patients diagnosed from 2006 to 2009. Although novel agents were introduced to both countries which have compatible healthcare standards at the same time, MM patients with high-risk features in SG could receive frontline bortezomib while bortezomib could only be approved for salvage setting in SK. After a median follow-up of 19 months, despite 26% of patients in SG versus none in SK having received frontline bortezomib, the overall bortezomib-exposure rate was higher in SK (60% versus 47%, p< 0.001). Significantly more patients had no response to induction in SK. Although the median overall survival (OS) of patients in SG and SK was not significantly different (not reached versus 4.83 years respectively, p= 0.2), corresponding 2-year OS for high-risk ISS patients treated in SG and SK was 81% and 67% respectively (p= 0.01). On multivariate analysis stratified by country, the attainment of ≥VGPR was the only significant prognostic factor in SG while the presence of high-risk ISS has significant early prognostic impact in SK. Frontline use of bortezomib compared to its sequential may avert early mortality especially among patients with high-risk MM. © 2013 Elsevier Ltd.
Source Title: Leukemia Research
URI: http://scholarbank.nus.edu.sg/handle/10635/125464
ISSN: 01452126
DOI: 10.1016/j.leukres.2013.06.008
Appears in Collections:Staff Publications

Show full item record
Files in This Item:
There are no files associated with this item.

SCOPUSTM   
Citations

12
checked on Sep 17, 2020

WEB OF SCIENCETM
Citations

12
checked on Sep 17, 2020

Page view(s)

52
checked on Sep 19, 2020

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.